Anika Therapeutics is commencing full U.S. commercial launch of TACTOSET surgically-delivered therapy for bone repair procedures, following the initial launch in late 3Q19.
TACTOSET combines calcium phosphate with hyaluronic acid to treat bone voids and skeletal defects caused by trauma or age-related degeneration and is the company's first product to launch under its U.S.-based hybrid commercial model.
The hybrid sales model will allow the product to launch in various phases and to scale where appropriate, as TACTOSET is introduced across multiple categories in the orthopedic segment. The commercial team gains more precise commercial control, including greater visibility on product demand, end-user activity, and fulfillment.
“We are proud to commence the full-scale launch of TACTOSET, our first surgically delivered regenerative therapy in the U.S. sold through our hybrid commercial sales channel,” said Joseph Darling, Anika's President and Chief Executive Officer. “TACTOSET has already surpassed our initial goals of onboarding five distributor agents and being present in ten surgical centers in 2019.”